Research menu
Jump to menu

Publications:  Prof Marta Korbonits

Hernández-Ramírez LC, Morgan RML, Barry S et al.(2018). Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland. Oncotarget vol. 9, (10) 9177-9198.
Iacovazzo D, Flanagan SE, Walker E et al.(2018). MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A vol. 115, (5) 1027-1032.
Marques P, Spencer R, Morrison PJ et al.(2018). Cantú syndrome with coexisting familial pituitary adenoma. Endocrine1-8.
Pérez-Rivas LG, Theodoropoulou M, Puar TH et al.(2018). SomaticUSP8mutations are frequent events in corticotroph tumor progression causing Nelson's tumor. Eur J Endocrinol vol. 178, (1) 59-65.
Tufton N, Roncaroli F, Hadjidemetriou I et al.(2017). Pituitary Carcinoma in a Patient with an SDHB Mutation. Endocr Pathol vol. 28, (4) 320-325.
Araujo PB, Kasuki L, de Azeredo Lima CH et al.(2017). AIP mutations in brazilian patients with sporadic pituitary adenomas: A single-center evaluation. Endocrine Connections vol. 6, (8) 914-925.
Ribeiro-Oliveira A, Korbonits M, Freire C(2017). Echocardiographic improvements following transsphenoidal surgery for acromegaly. Neurology India vol. 65, (6) 1225-1226.
Stelmachowska-Banas M, Zgliczynski W, Tutka P et al.(2017). Fatal Carney Complex in Siblings Due to De Novo Large Gene Deletion. J Clin Endocrinol Metab vol. 102, (11) 3924-3927.
Salvatori R, Radian S, Diekmann Y et al.(2017). In-frame seven amino-acid duplication inAIParose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. Eur J Endocrinol vol. 177, (3) 257-266.
Koehler VF, Jungheim K, Groß U et al.(2017). Novel Germline p.Gly42ValMEN1Mutation in a Family with Multiple Endocrine Neoplasia Type 1 - Excellent Response of Prolactinoma to Cabergoline. Ann Clin Lab Sci vol. 47, (5) 606-610.
Ibáñez-Costa A, Korbonits M(2017). AIP and the somatostatin system in pituitary tumours. Journal of Endocrinology vol. 235, (3) R101-R116.
Ibáñez-Costa A, Korbonits M(2017). AIP and the somatostatin system in pituitary tumours. J Endocrinol vol. 235, (3) R101-R116.
Kiefer FW, Winhofer Y, Iacovazzo D et al.(2017). PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex. Eur J Endocrinol vol. 177, (2) K7-K12.
Butz H, Németh K, Czenke D et al.(2017). Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas. Pathology and Oncology Research vol. 23, (3) 633-641.
Marques P, Korbonits M(2017). Genetic Aspects of Pituitary Adenomas. Endocrinology and Metabolism Clinics of North America vol. 46, (2) 335-374.
Shaid M, Korbonits M(2017). Genetics of pituitary adenomas. Neurology India vol. 65, (3) 577-587.
Bulwer C, Conn R, Shankar A et al.(2017). Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clinical Endocrinology
Doleschall M, Luczay A, Koncz K et al.(2017). A unique haplotype of RCCX copy number variation: from the clinics of congenital adrenal hyperplasia to evolutionary genetics. Eur J Hum Genet vol. 25, (6) 702-710.
Asa SL, Casar-Borota O, Chanson P et al.(2017). From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer vol. 24, (4) C5-C8.
Iacovazzo D, Hernández-Ramírez LC, Korbonits M(2017). Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. Expert Review of Endocrinology and Metabolism vol. 12, (2) 143-153.
Thomas JDJ, Dattani A, Zemrak F et al.(2017). Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients. Experimental and Clinical Endocrinology and Diabetes
Mitra MT, Jönsson P, Åkerblad AC et al.(2017). Social, educational and vocational outcomes in patients with childhood-onset and young-adult-onset growth hormone deficiency. Clinical Endocrinology
Roncaroli F, Iacovazzo D, Rodd C et al. (2017). Distinct pathological features of pituitary adenomas in patients with X-linked acrogigantism (XLAG). NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. Conference: 118th Meeting of the British-Neuropathological-Society vol. 43, 20-20.
Tufton N, Shapiro L, Srirangalingam U et al.(2017). Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. Clin Endocrinol (Oxf) vol. 86, (2) 286-296.
Roncaroli F, Tufton N, Hadjidemetriou I et al. (2017). Pituitary carcinoma in a patient with germline Succinate Dehydrogenase B mutation. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. Conference: 118th Meeting of the British-Neuropathological-Society vol. 43, 46-46.
Srirangalingam U, Banerjee A, Patki P et al.(2017). Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas. Clinical Genitourinary Cancer vol. 15, (1) e131-e136.
Gadelha MR, Kasuki L, Korbonits M(2017). The genetic background of acromegaly. Pituitary vol. 20, (1) 10-21.
Seelig E, Meyer S, Timper K et al.(2017). Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol vol. 176, (3) 349-358.
Radian S, Diekmann Y, Gabrovska P et al.(2017). Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland. Hum Mutat vol. 38, (1) 78-85.
Iacovazzo D, Caswell R, Bunce B et al.(2016). Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathologica Communications vol. 4, (1)
Caimari F, Korbonits M(2016). Novel genetic causes of pituitary adenomas. Clinical Cancer Research vol. 22, (20) 5030-5042.
Iacovazzo D, Korbonits M(2016). Gigantism: X-linked acrogigantism and GPR101 mutations. Growth Horm IGF Res vol. 30-31, 64-69.
Ramírez-Rentería C, Hernández-Ramírez LC, Portocarrero-Ortiz L et al.(2016). AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience. Endocrine vol. 53, (2) 402-411.
Hernández-Ramírez LC, Martucci F, Morgan RML et al.(2016). Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations. Journal of Clinical Endocrinology and Metabolism vol. 101, (8) 3144-3154.
Ferreira VM, Marcelino M, Piechnik SK et al.(2016). Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. J Am Coll Cardiol vol. 67, (20) 2364-2374.
Vujovic S, Vujosevic S, Kavaric S et al.(2016). Cancerous leptomeningitis and familial congenital hypopituitarism. Endocrine vol. 52, (2) 231-235.
Rodd C, Millette M, Iacovazzo D et al.(2016). Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)—Diagnosis and Management. The Journal of Clinical Endocrinology & Metabolism vol. 101, (5) 1927-1930.
Bolger GB, Bizzi MF, Pinheiro SV et al.(2016). cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors. Endocrine-Related Cancer vol. 23, (5) 419-431.
Koehler VF, Jungheim K, Gross U et al. (2016). Novel germline p.Gly42Val MEN1 mutation in a family with multiple endocrine neoplasia type 1.
Dutta P, Korbonits M, Sachdeva N et al.(2016). Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?. Neurology India vol. 64, (2) 252-258.
Syro LV, Rotondo F, Kovacs K et al.(2016). Clinicopathologic features of familial pituitary adenomas. Diagnostic Histopathology vol. 22, (3) 85-91.
Strasburger CJ, Karavitaki N, Störmann S et al.(2016). Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol vol. 174, (3) 355-362.
Iacovazzo D, Carlsen E, Lugli F et al.(2016). Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol vol. 174, (2) 241-250.
Scagliotti V, Avagliano L, Gualtieri A et al.(2016). Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma. Pituitary vol. 19, (1) 50-56.
Scagliotti V, Avagliano L, Gualtieri A et al.(2016). Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma. Pituitary vol. 19, (1) 50-56.
Hernandez-Ramirez LC, Morgan RML, Chrisostomos Prodromou C et al. (2016). A Proteomic Approach to Unveil the Pituitary-Specific Tumour Suppressor Mechanisms of AIP. Conference: Endocr. RevSUN-505.
Portocarrero-Ortiz L, Martinez-Gigena MP, Alcocer-Barradas V et al. (2016). Clinical Case : Gigantism Due to AIP Mutation in a 9 Years-Old Identical Twin. Conference: Endocr. RevSUN-566.
Caimari F, Dang MN, Hernandez-Ramirez LC et al. (2016). Clinical Characteristics Predicting AIP Mutation Status in Pituitary Adenoma Patients. Conference: Endocr. RevOR42-OR45.
Korbonits M, Dutta P, Reddy KS et al. (2016). Exome Sequencing Reveals Double Hit By AIP Gene Mutation and Copy Loss of Chromosome 11 but Negative X-LAG in a Pituitary Adenoma of a 4 Yrs Child with Gigantism Treated with Multimodal Therapy. Conference: Endocr. RevLBSat-27.
Scudder CJ, Mirczuk SM, Richardson KM et al. (2016). Feline Hypersomatotropism As a Spontaneous Animal Model of Acromegaly: Molecular Analyses of Somatostatin and Dopamine Receptor Expression in GH-Secreting Adenomas in the Cat (Felis catus). Conference: Endocr. RevLBSat-29.
Iacovazzo D, Kapur S, Bunce B et al. (2016). GPR101 Variants in Acromegaly: Results from a Large Series of Patients. Conference: Endocr. RevSUN-534.
Dworakowska D, Paulina Szyszka P, Diaz-Cano SJ et al. (2016). Metformin Alters an Anti-Proliferative Effect of Mitotane in a Human Adrenocortical Cancer (H295R) Cell Line: Preliminary Results. Conference: Endocr. RevSAT-411.
Korbonits M, Millette M, Iacovazzo D et al. (2016). Somatic Xq26.3 Microduplication Causing X-Linked Acrogigantism (X-LAG). Conference: Endocr. RevLBSat-28.
Iacovazzo D, Jose S, Bunce B et al. (2016). X-Linked Acrogigantism (X-LAG): Novel Histopathological and Clinical Characterisation. Conference: Endocr. RevOR42-OR44.
Renukanthan A, Quinton R, Turner B et al.(2015). Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia. Endocrine vol. 50, (2) 496-503.
Agustsson TT, Baldvinsdottir T, Jonasson JG et al.(2015). The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol vol. 173, (5) 655-664.
Ferraù F, Korbonits M (2015). Metabolic comorbidities in Cushing's syndrome. Eur J Endocrinol. vol. 173, M133-M157.
Hernández-Ramírez LC, Gabrovska P, Dénes J et al.(2015). Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab vol. 100, (9) E1242-E1254.
Ribeiro-Oliveira A, Marques MB, Vilas-Boas WW et al.(2015). The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress. J Renin Angiotensin Aldosterone Syst vol. 16, (3) 481-487.
O'Toole SM, Dénes J, Robledo M et al.(2015). 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocr Relat Cancer vol. 22, (4) T105-T122.
Kumar S, Yadav RN, Gupta P et al.(2015). Prostatic hyperplasia in acromegaly, a myth or reality: a case-control study. Eur J Endocrinol vol. 173, (2)
Perez-Rivas LG, Theodoropoulou M, Ferraù F et al.(2015). The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. J Clin Endocrinol Metab vol. 100, (7) E997-1004.
Müller TD, Nogueiras R, Andermann ML et al.(2015). Ghrelin. Mol Metab vol. 4, (6) 437-460.
Lim SV, Marenzana M, Hopkinson M et al.(2015). Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength. Endocrinology vol. 156, (4) 1362-1371.
Gardner CJ, Mattsson AF, Daousi C et al.(2015). GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database. Eur J Endocrinol vol. 172, (4) 371-381.
Melmed S, Popovic V, Bidlingmaier M et al.(2015). Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab vol. 100, (4) 1699-1708.
Dénes J, Swords F, Rattenberry E et al.(2015). Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab vol. 100, (3) E531-E541.
Ferreira VM, Marcelino M, Piechnik SK et al.(2015). Multi-parametric cardiovascular magnetic resonance imaging detects subclinical myocardial involvement in patients diagnosed with phaeochromocytoma. Journal of Cardiovascular Magnetic Resonance1-2.
Diaz-Cano S, Szyszka P, Weitsman G et al. (2015). Effect of Erlotinib on Proliferation and Steriodogenesis in Primary Cultures of Adrenocortical Carcinoma. MODERN PATHOLOGY. vol. 28, 133A-133A.
Soh LM, Druce M, Grossman AB et al.(2015). Evaluation of genotype-phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome. Eur J Endocrinol vol. 172, (2) 217-226.
Kumar S, Yadav RN, Gupta P et al.(2015). Prostatic hyperplasia in acromegaly, a myth or reality: a case-control study. Eur J Endocrinol vol. 172, (2) 97-106.
Glynn NGL, Korbonits M(2015). A 25-year-old woman with headache and joint pain. Endocrinology and Diabetes: Case Studies, Questions and Commentaries,
Iacovazzo D, Piacentini S, Lugli F et al. (2015). A Novel MEN1 Gene Variant in a Sporadic Case of Multiple Endocrine Neoplasia Type 1. NEUROENDOCRINOLOGY. vol. 102, 150-150.
Nölting S, Maurer J, Spöttl G et al.(2015). Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PLoS One vol. 10, (12)
Dutta P, Hajela A, Pathak A et al.(2015). Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team. Neurology India vol. 63, (3) 360-368.
Dénes J, Kasuki L, Trivellin G et al.(2015). Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS One vol. 10, (2)
Niessen SJM, Forcada Y, Mantis P et al.(2015). Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter. PLoS One vol. 10, (5)
Larkin SJ, Ferraù F, Karavitaki N et al.(2014). Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. Eur J Endocrinol vol. 171, (6) 705-710.
Preda V, Korbonits M, Cudlip S et al.(2014). Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. Eur J Endocrinol vol. 171, (5) 659-666.
Solomou S, Korbonits M(2014). The role of ghrelin in weight-regulation disorders: implications in clinical practice. Hormones (Athens) vol. 13, (4) 458-475.
Iacovazzo D, Sampson JR, Morrison PJ et al.(2014). Five families with RET-mutation negative familial medullary thyroid carcinoma: what lies beyond RET?. WIENER KLINISCHE WOCHENSCHRIFT vol. 126, S141-S142.
Nölting S, Giubellino A, Tayem Y et al.(2014). Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice. Endocrinology vol. 155, (7) 2377-2390.
de Kock L, Sabbaghian N, Plourde F et al.(2014). Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol vol. 128, (1) 111-122.
Tritos NA, Johannsson G, Korbonits M et al.(2014). Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis. J Clin Endocrinol Metab vol. 99, (6) 2018-2029.
Iacovazzo D, Morrison PJ, Foulkes W et al.(2014). Four Families with RET-Mutation Negative Familial Medullary Thyroid Carcinoma: What Lies Beyond RET?. ENDOCRINE REVIEWS vol. 35, (3)
Butz H, Szabo PM, Igaz P et al. (2014). Integrative Analysis of Chromosomal, Trancriptome, Proteomic and Mirnome Data Reveals Involvement of Impaired Developmental Processes in Clinically Non-Functional Pituitary Adenoma Formation. ENDOCRINE REVIEWS. vol. 35,
Radian S, Gabrovska P, Holland B et al. (2014). Population Screening for the Irish Founder AIP Mutation R304*Reveals a Prevalence of 1/500 in the Local Population, While High Mutation Frequency Is Present Among Irish Familial and Sporadic Somatotropinoma Patients. ENDOCRINE REVIEWS. vol. 35,
Dworakowska D, Dudka D, Weitsman G et al.(2014). Simultaneous Targeting PI3K/Akt/mTOR and MEK/RAF/ERK Pathways Results in a Synergistic Anti-Proliferative Effect in an Adrenocortical Carcinoma Model. ENDOCRINE REVIEWS vol. 35, (3)
Soh LM, Druce M, Grossman AB et al. (2014). Strong Genotype-Phenotype Correlation in Pendred Syndrome Allows Reduced Endocrine Follow-up in Suitable Patients. ENDOCRINE REVIEWS. vol. 35,
Aflorei ED, Korbonits M(2014). Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol vol. 117, (3) 379-394.
Pernicova I, Korbonits M(2014). Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol vol. 10, (3) 143-156.
Stadler M, Tomann L, Storka A et al.(2014). Effects of smoking cessation on b-cell function, insulin sensitivity, body weight, and appetite. European Journal of Endocrinology vol. 170, (2) 219-227.
Stadler M, Krššák M, Jankovic D et al.(2014). Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery. Clin Endocrinol (Oxf) vol. 80, (2) 208-213.
Doleschall M, Szabó JA, Pázmándi J et al.(2014). Common genetic variants of the human steroid 21-hydroxylase gene (CYP21A2) are related to differences in circulating hormone levels. PLoS One vol. 9, (9)
Alband N, Korbonits M(2014). Familial pituitary tumors. Handb Clin Neurol vol. 124, 339-360.
Garcia EA, Trivellin G, Aflorei ED et al.(2013). Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?. J Clin Endocrinol Metab vol. 98, (12) E1918-E1926.
Kola B, Wittman G, Bodnár I et al.(2013). The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. FASEB J vol. 27, (12) 5112-5121.
Gadelha MR, Kasuki L, Dénes J et al.(2013). MicroRNAs: Suggested role in pituitary adenoma pathogenesis. J Endocrinol Invest vol. 36, (10) 889-895.
Scerif M, Füzesi T, Thomas JD et al.(2013). CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. J Endocrinol vol. 219, (1) 79-88.
Rattenberry E, Vialard L, Yeung A et al.(2013). A Comprehensive Next Generation Sequencing-Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM vol. 98, (7) E1248-E1256.
Gadelha MR, Kasuki L, Korbonits M(2013). Novel pathway for somatostatin analogs in patients with acromegaly. TRENDS IN ENDOCRINOLOGY AND METABOLISM vol. 24, (5) 238-246.
Hernández-Ramírez LC, Korbonits M(2013). Familial Pituitary Adenomas. Pituitary Disorders: Diagnosis and Management,
Occhi G, Regazzo D, Trivellin G et al.(2013). A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. PLOS GENETICS vol. 9, (3) Article ARTN e1003350,
Lim CT, Kola B, Feltrin D et al.(2013). Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. Mol Cell Endocrinol vol. 365, (2) 303-308.
Kovács GL, Góth M, Rotondo F et al.(2013). ACTH-secreting Crooke cell carcinoma of the pituitary. Eur J Clin Invest vol. 43, (1) 20-26.
Williams F, Hunter S, Bradley L et al.(2013). Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. Journal of Clinical Endocrinology and Metabolism vol. 99, (4) 1122-1131.
Gadelha MR, Trivellin G, Hernandez-Ramirez LC et al.(2013). Genetics of Pituitary Adenomas. ENDOCRINE TUMOR SYNDROMES AND THEIR GENETICS vol. 41, 111-140.
Gueorguiev M, Korbonits M(2013). Genetics of the ghrelin system. Endocr Dev vol. 25, 25-40.
Martucci F, Trivellin G, Korbonits M(2012). Familial isolated pituitary adenomas: an emerging clinical entity. J Endocrinol Invest vol. 35, (11) 1003-1014.
Guaraldi F, Corazzini V, Gallia GL et al.(2012). Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor. Pituitary vol. 15 Suppl 1, S61-S67.
Boguszewski CL, Fighera TM, Bornschein A et al.(2012). Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma. ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA vol. 56, (8) 507-512.
Nölting S, Garcia E, Alusi G et al.(2012). Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol vol. 49, (2) 79-96.
Trivellin G, Butz H, Delhove J et al.(2012). MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. Am J Physiol Endocrinol Metab vol. 303, (6) E708-E719.
Korbonits M, Storr H, Kumar AV(2012). Familial pituitary adenomas - who should be tested for AIP mutations?. Clin Endocrinol (Oxf) vol. 77, (3) 351-356.
Jeyabalan J, Shah M, Viollet B et al.(2012). Mice lacking AMP-activated protein kinase α1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment. J Endocrinol vol. 214, (3) 349-358.
Marques MB, Jr R-OA, Guimaraes J et al.(2012). Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker. STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS vol. 15, (5) 554-561.
Thompson IR, Chand AN, King PJ et al.(2012). Expression of guanylyl cyclase-B (GC-B/NPR2) receptors in normal human fetal pituitaries and human pituitary adenomas implicates a role for C-type natriuretic peptide. Endocr Relat Cancer vol. 19, (4) 497-508.
Diggle CP, Parry DA, Logan CV et al.(2012). Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. HUMAN MUTATION vol. 33, (8) 1175-1181.
Chahal HS, Trivellin G, Leontiou CA et al.(2012). Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab vol. 97, (8) E1411-E1420.
Alexandraki KI, Munayem Khan M, Chahal HS et al.(2012). Oncogene-induced senescence in pituitary adenomas and carcinomas. Hormones (Athens) vol. 11, (3) 297-307.
Korbonits M(2012). Molecular biology of pituitary tumours. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION vol. 42, 49-50.
Butz H, Liko I, Czirjak S et al.(2012). miR expression profile reveals alterations of G2/M transition of cell cycle in pituitary adenomas. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION vol. 42, 50-50.
Lim CT, Korbonits M(2012). Paediatric endocrine aspects of ghrelin. Pediatr Endocrinol Rev vol. 9, (3) 628-638.
Zemrak F, Thomas J, Dattani A et al. (2012). Cardiovascular changes in patients with acromegaly assessed by CMR. J Cardiovasc Magn Reson. vol. 14 Suppl 1,
Dattani A, Thomas J, Zemrak F et al. (2012). Cardiovascular changes in patients with adult-onset growth hormone deficiency assessed by CMR. J Cardiovasc Magn Reson. vol. 14 Suppl 1,
Noelting S, Garcia E, Alusi G et al. (2012). Combined Blockade of Several Signalling Pathways Shows Marked Anti-Tumor Potential in Two Novel Mouse Phaeochromocytoma Cell Lines. NEUROENDOCRINOLOGY. vol. 96, 10-11.
Scerif M, Kola B, Korbonits M(2012). Ghrelin regulation of AMPK in the hypothalamus and peripheral tissues. Ghrelin in Health and Disease,
Lim CT, Lolli F, Thomas JD et al.(2012). Measurement of AMP-activated protein kinase activity and expression in response to ghrelin. Methods Enzymol vol. 514, 271-287.
Miljic P, Miljic D, Cain JW et al.(2012). Pathogenesis of vascular complications in Cushing's syndrome. HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM vol. 11, (1) 21-30.
Morgan RML, Hernández-Ramírez LC, Trivellin G et al.(2012). Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal α-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition. PLoS One vol. 7, (12)
Liu B, Garcia EA, Korbonits M(2011). Genetic studies on the ghrelin, growth hormone secretagogue receptor (GHSR) and ghrelin O-acyl transferase (GOAT) genes. Peptides vol. 32, (11) 2191-2207.
Cai W, Kramarova TV, Berg P et al.(2011). The Immunophilin-Like Protein XAP2 Is a Negative Regulator of Estrogen Signaling through Interaction with Estrogen Receptor alpha. PLOS ONE vol. 6, (10) Article e25201,
Lim CT, Kola B, Korbonits M(2011). The ghrelin/GOAT/GHS-R system and energy metabolism. Rev Endocr Metab Disord vol. 12, (3) 173-186.
Trivellin G, Korbonits M(2011). AIP and its interacting partners. J Endocrinol vol. 210, (2) 137-155.
Scerif M, Goldstone AP, Korbonits M(2011). Ghrelin in obesity and endocrine diseases. Mol Cell Endocrinol vol. 340, (1) 15-25.
Butz H, Likó I, Czirják S et al.(2011). MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas. Pituitary vol. 14, (2) 112-124.
Stals K, Trivellin G, Korbonits M(2011). AIP Mutation in Pituitary Adenomas REPLY. NEW ENGL J MED vol. 364, (20) 1974-1975.
Stals K, Trivellin G, Korbonits M(2011). The authors and a colleague reply. New England Journal of Medicine vol. 364, (20) 1974-1975.
Shah M, Viollet B, Korbonits M et al. (2011). Deletion of Amp-activated Protein Kinase (AMPK)-Alpha 1 catalytic subunit in mice impairs the in vivo response of bones to hormonal challenges. BONE. vol. 48, S96-S96.
Alexandraki KI, Kaltsas GA, Vouliotis A-I et al.(2011). Specific electrocardiographic features associated with Cushing's disease. Clin Endocrinol (Oxf) vol. 74, (5) 558-564.
Dénes J, Korbonits M, Hubina E et al.(2011). [Familial isolated pituitary adenoma syndrome]. Orv Hetil vol. 152, (18) 722-730.
Scerif M, Goldstone AP, Korbonits M(2011). Ghrelin in Obesity and Endocrine Diseases. Mol Cell Endocrinol
Chahal HS, Stals K, Unterländer M et al.(2011). AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med vol. 364, (1) 43-50.
Chahal HS, Stals K, Unterlander M et al.(2011). Brief Report: AIP Mutation in Pituitary Adenomas in the 18th Century and Today. NEW ENGL J MED vol. 364, (1) 43-50.
Chahal HS, Ansorge O, Karavitaki N et al.(2011). Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro. Horm Res Paediatr vol. 76 Suppl 1, 111-112.
Lim CT, Kola B, Grossman A et al.(2011). The expression of ghrelin O-acyltransferase (GOAT) in human tissues. Endocr J vol. 58, (8) 707-710.
Dworakowska D, Korbonits M, Aylwin S et al.(2011). The pathology of pituitary adenomas from a clinical perspective. Frontiers in Bioscience - Scholar vol. 3 S, (1) 105-116.
Dworakowska D, Korbonits M, Aylwin S et al.(2011). The pathology of pituitary adenomas from a clinical perspective. Front Biosci (Schol Ed) vol. 3, 105-116.
Grisouard J, Timper K, Radimerski TM et al.(2010). Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. BIOCHEM PHARMACOL vol. 80, (11) 1736-1745.
de Pinho LKJ, Neto LV, Wildemberg LEA et al.(2010). Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening. ARQ BRAS ENDOCRINOL vol. 54, (8) 698-704.
Butz H, Likó I, Czirják S et al.(2010). Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. J Clin Endocrinol Metab vol. 95, (10) E181-E191.
Ozfirat Z, Korbonits M(2010). AIP gene and familial isolated pituitary adenomas. Mol Cell Endocrinol vol. 326, (1-2) 71-79.
Musat M, Morris DG, Korbonits M et al.(2010). Cyclins and their related proteins in pituitary tumourigenesis. MOL CELL ENDOCRINOL vol. 326, (1-2) 25-29.
Cain JW, Miljic D, Popovic V et al.(2010). Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma. Expert Review of Endocrinology and Metabolism vol. 5, (5) 681-695.
Dénes J, Korbonits M, Hubina E et al.(2010). [Treatment of acromegaly]. Orv Hetil vol. 151, (34) 1384-1393.
Langouche L, Vander Perre S, Thiessen S et al.(2010). Alterations in Adipose Tissue during Critical Illness An Adaptive and Protective Response?. AM J RESP CRIT CARE vol. 182, (4) 507-516.
Shah M, Kola B, Bataveljic A et al.(2010). AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. BONE vol. 47, (2) 309-319.
Igreja S, Chahal HS, King P et al.(2010). Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat vol. 31, (8) 950-960.
Stilling G, Sun ZF, Zhang SY et al.(2010). MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and-493 in pituitary carcinomas. ENDOCRINE vol. 38, (1) 67-75.
Chahal HS, Chapple JP, Frohman LA et al.(2010). Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab vol. 21, (7) 419-427.
Chahal HS, Alband N, Ansorge O et al. (2010). AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies. ENDOCRINE REVIEWS. vol. 31,
Righi A, Zhang SY, Jin L et al.(2010). Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues. ENDOCR PATHOL vol. 21, (1) 25-31.
Gadelha MR, Kasuki L, Neto LV et al.(2010). Pathogenesis of GH-secreting adenomas. ENDOCR J vol. 57, S282-S282.
Lim CT, Kola B, Korbonits M(2010). AMPK as a mediator of hormonal signalling. J Mol Endocrinol vol. 44, (2) 87-97.
Lim CT, Kola B, Korbonits M et al.(2010). Ghrelin's role as a major regulator of appetite and its other functions in neuroendocrinology. Prog Brain Res vol. 182, 189-205.
Tahir A, Chahal HS, Korbonits M(2010). Molecular genetics of the aip gene in familial pituitary tumorigenesis. Prog Brain Res vol. 182, 229-253.
Dworakowska D, Wlodek E, Leontiou CA et al.(2009). Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer vol. 16, (4) 1329-1338.
Chahal HS, Ajith Kumar VA, Korbonits M(2009). Familial isolated pituitary adenomas. US Endocrinology vol. 5, 104-107.
Butler H, Korbonits M(2009). Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol vol. 161, (5) 655-662.
Grisouard J, Kinter DS, Radimerski T et al. (2009). AMP-activated protein kinase (AMPK) modulates lipopolysaccharide (LPS)-induced cytokine expression and lipolysis in human adipocytes. DIABETOLOGIA. vol. 52, S253-S253.
Kola B, Korbonits M(2009). Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation. J Endocrinol vol. 202, (2) 191-198.
Garcia EA, King P, Sidhu K et al.(2009). The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes. Eur J Endocrinol vol. 161, (2) 307-315.
Gueorguiev M, Lecoeur C, Meyre D et al.(2009). Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity. Obesity (Silver Spring) vol. 17, (4) 745-754.
Korbonits M, Carlsen E (2009). Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res. vol. 71 Suppl 2, 123-130.
Igreja S, Chahal HS, Akker SA et al.(2009). Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf) vol. 70, (2) 259-264.
Gueorguiev M, Lecoeur C, Benzinou M et al.(2009). A genetic study of the ghrelin and growth hormone secretagogue receptor (GHSR) genes and stature. Ann Hum Genet vol. 73, (1) 1-9.
Leontiou CA, Gueorguiev M, Hassan S et al. (2009). AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation. HORMONE RESEARCH. vol. 71, 149-150.
Musat M, Korbonits M, Grossman A(2009). STOP AKTING TO TREAT ENDOCRINE TUMOURS. ACTA ENDOCRINOL vol. 5, (1) 131-142.
Kola B, Christ-Crain M, Lolli F et al.(2008). Changes in Adenosine 5 '-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing's Syndrome. J CLIN ENDOCR METAB vol. 93, (12) 4969-4973.
Ribeiro-Oliveira A, Franchi G, Kola B et al.(2008). Protein western array analysis in human pituitary tumours: insights and limitations. Endocr Relat Cancer vol. 15, (4) 1099-1114.
Gibson C, Korbonits M(2008). The Yin and Yang of the Ghrelin gene products. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry vol. 8, (4) 292-302.
Ribeiro-Oliveira A, Korbonits M, Grossman AB(2008). The potential role of D-2 dopamine receptors as a target in the management of neuroendocrine tumors. CANCER BIOL THER vol. 7, (12) 1979-1981.
Garcia EA, Heude B, Petry CJ et al.(2008). Ghrelin receptor gene polymorphisms and body size in children and adults. J CLIN ENDOCR METAB vol. 93, (10) 4158-4161.
Grisouard J, Radimerski T, Kinter DS et al.(2008). Effects of the AMPK activators AICAR and metformin on basal and insulin-induced glucose-uptake in human adipocytes. DIABETOLOGIA vol. 51, S313-S314.
Shah M, Kola B, Sunters A et al. (2008). Neuroendocrine Activation of AMP-activated Protein Kinase (AMPK) in Osteoblasts. JOURNAL OF BONE AND MINERAL RESEARCH. vol. 23, S251-S251.
Grozinsky-Glasberg S, Shimon I, Korbonits M et al.(2008). Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. ENDOCR-RELAT CANCER vol. 15, (3) 701-720.
Varga M, Rajczy K, Telkes G et al.(2008). HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients. Nephrol Dial Transplant vol. 23, (8) 2673-2678.
Christ-Crain M, Kola B, Lolli F et al.(2008). AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J vol. 22, (6) 1672-1683.
Leontiou CA, Gueorguiev M, van der Spuy J et al.(2008). The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab vol. 93, (6) 2390-2401.
Grozinsky-Glasberg S, Grossman AB, Korbonits M(2008). The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol vol. 286, (1-2) 238-250.
Zavarella S, Petrone A, Zampetti S et al.(2008). A new variation in the promoter region, the -604 C > T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance. INT J OBESITY vol. 32, (4) 663-668.
Kola B, Farkas I, Christ-Crain M et al.(2008). The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One vol. 3, (3)
Shah M, Kola B, Sunters A et al.(2008). AMP-activated protein kinase (AMPK) plays a role in osteoblast function. CALCIFIED TISSUE INT vol. 82, S117-S117.
van Thuijl H, Kola B, Korbonits M(2008). Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase. Vitam Horm vol. 77, 121-148.
Korbonits M(2008). Obesity and metabolism. Preface. Front Horm Res vol. 36,
Grozinsky-Glasberg S, Franchi G, Teng M et al.(2008). Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology vol. 87, (3) 168-181.
Kola B, Grossman AB, Korbonits M(2008). The role of AMP-activated protein kinase in obesity. Front Horm Res vol. 36, 198-211.
Samsuddin S, Glyn M, Kola B et al. (2007). A direct effect of ghrelin to augment cardiac AMPK activity is compromised by hyperglycaemia following ischaemia/reperfusion. DIABETOLOGIA. vol. 50, S490-S490.
Radimerski T, Seboek D, Kola B et al. (2007). Differential effects of 5AMP-activated protein kinase (AMPK) activation by metformin and AICAR on glucose uptake and lipolysis in human adipocytes. DIABETOLOGIA. vol. 50, S232-S232.
Christ-Crain M, Kola B, Lolli F et al.(2007). The role of AMP-activated protein kinase in the metabolic syndrome. OBES METAB-MILAN vol. 3, (3) 143-154.
Korbonits M, Blaine D, Elia M et al.(2007). Metabolic and hormonal changes during the refeeding period of prolonged fasting. EUR J ENDOCRINOL vol. 157, (2) 157-166.
Gueorguiev M, Wiltshire S, Garcia EA et al.(2007). Examining the candidacy of ghrelin as a gene responsible for variation in adult stature in a United Kingdom population with type 2 diabetes. J CLIN ENDOCR METAB vol. 92, (6) 2201-2204.
Ewing I, Pedder-Smith S, Franchi G et al.(2007). A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) vol. 66, (3) 348-352.
Leontiou CA, Franchi G, Korbonits M(2007). Ghrelin in neuroendocrine organs and tumours. Pituitary vol. 10, (3) 213-225.
Higgins SC, Gueorguiev M, Korbonits M(2007). Ghrelin, the peripheral hunger hormone. Ann Med vol. 39, (2) 116-136.
Swales KE, Korbonits M, Carpenter R et al.(2006). The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res vol. 66, (20) 10120-10126.
Christ-Crain M, Stoeckli R, Ernst A et al.(2006). Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients. J Clin Endocrinol Metab vol. 91, (9) 3544-3547.
Jackson JM, Blaine D, Powell-Tuck J et al.(2006). Macro- and micronutrient losses and nutritional status resulting from 44 days of total fasting in a non-obese man. NUTRITION vol. 22, (9) 889-897.
Emery MN, Leontiou C, Bonner SE et al.(2006). PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. CLIN ENDOCRINOL vol. 65, (3) 389-395.
Zampetti S, Zavarella S, Petrone A et al. (2006). The role of Leu72Met and-604 C > T polymorphisms of the ghrelin gene on insulin resistance in Italian population. DIABETOLOGIA. vol. 49, 225-226.
Hubina E, Nanzer AM, Hanson MR et al.(2006). Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol vol. 155, (2) 371-379.
Kola B, Boscaro M, Rutter GA et al.(2006). Expanding role of AMPK in endocrinology. TRENDS ENDOCRIN MET vol. 17, (5) 205-215.
García EA, Korbonits M(2006). Ghrelin and cardiovascular health. Curr Opin Pharmacol vol. 6, (2) 142-147.
Hubina E, Ruscica M, Nanzer AM et al.(2005). Novel molecular aspects of pituitary adenomas. Journal of endocrinological investigation. vol. 28, (11 Suppl) 87-92.
Góth M, Hubina E, Korbonits M(2005). Relationship between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome. Orvosi Hetilap vol. 146, (2) 51-55.
Korbonits M, Blaine D, Elia M et al.(2005). Refeeding David Blaine--studies after a 44-day fast. N Engl J Med vol. 353, (21) 2306-2307.
Bonner SE, Morris DG, Korbonits M et al. (2005). The roles of CyclinE, Jab1 and archipelago in breast cancer cell cycle dysregulation. BRITISH JOURNAL OF SURGERY. vol. 92, 1309-1309.
Dahia PLM, Ross KN, Wright ME et al.(2005). A HIF1 alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLOS GENET vol. 1, (1) Article e8, 72-80.
Kola B, Hubina E, Tucci SA et al.(2005). Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J BIOL CHEM vol. 280, (26) 25196-25201.
Morris DG, Musat M, Czirják S et al.(2005). Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol vol. 153, (1) 143-151.
Hubina E, Góth M, Korbonits M(2005). [Ghrelin--a hormone with multiple functions]. Orv Hetil vol. 146, (25) 1345-1351.
Musat M, Korbonits M, Kola B et al.(2005). Enhanced protein kinase B/Akt signalling in pituitary tumours. ENDOCR-RELAT CANCER vol. 12, (2) 423-433.
Goldstone AP, Patterson M, Kalingag N et al.(2005). Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab vol. 90, (5) 2681-2690.
Góth M, Hubina E, Korbonits M(2005). [Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome]. Orv Hetil vol. 146, (2) 51-55.
KORBONITS MJ, Thorner MO, Gaylinn BD et al.(2005). Growth Hormone–Releasing Hormone, Ghrelin and Growth Hormone Secretagogues: Basic Physiology and Clinical Implications. De Groot Clinical Endocrinology Elsevier
Korbonits M, GROSSMAN AB, Hubina E et al.(2005). Investigation of the intracellular effects of somatostatin analogs in pituitary adenomas. J Clin Endocrinol Metab
Hubina E, Ruscica M, Nanzer AM et al.(2005). Novel molecular aspects of pituitary adenomas. J Endocrinol Invest vol. 28, (11 Suppl International) 87-92.
KORBONITS MJ, Barnes PJ, Korbonits D et al.(2005). Theobromine inhibits sensory nerve activation and cough. FASEB J vol. 19, 231-233`.
Korbonits M, Kipnes M, Grossman AB(2004). Striant (TM) SR: a novel, effective and convenient testosterone therapy for male hypogonadism. INT J CLIN PRACT vol. 58, (11) 1073-1080.
Tucci SA, Rogers EK, Korbonits M et al.(2004). The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. BRIT J PHARMACOL vol. 143, (5) 520-523.
Usmani OS, Belvisi MG, Patel HJ et al.(2004). Theobromine inhibits sensory nerve activation and cough. FASEB J vol. 18, (14) 231-+.
Nanzer AM, Khalaf S, Mozid AM et al.(2004). Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol vol. 151, (2) 233-240.
Korbonits M, Grossman AB(2004). Ghrelin: update on a novel hormonal system. EUR J ENDOCRINOL vol. 151, S67-S70.
Gueorguiev M, Lecoeur C, Froguel R et al. (2004). Mutational analysis of ghrelin and the growth hormone secretagogue receptor. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. vol. 7, S56-S56.
Korbonits M, Slawik M, Cullen D et al.(2004). A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab vol. 89, (5) 2039-2043.
Góth M, Korbonits M(2004). [Therapy in acromegaly]. Orv Hetil vol. 145, (16) 867-871.
Goldstone AP, Thomas EL, Brynes AE et al.(2004). Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab vol. 89, (4) 1718-1726.
Korbonits M, Goldstone AP, Gueorguiev M et al.(2004). Ghrelin - a hormone with multiple functions. FRONT NEUROENDOCRIN vol. 25, (1) 27-68.
KORBONITS MJ, Hubina E, Goth MI(2004). Aetiology and demography of patients with GH deficiency in KIMS. Growth hormone deficiency in Adults - KIMS 10 years Anonymous
Grossman AB, Korbonits M(2004). Akting and cycling: a tale of the pituitary. Horm Res vol. 62 Suppl 3, 117-123.
Bonner SE, Morris DG, Korbonits M et al. (2004). Cell cycle dysregulation in breast cancer - the roles of Jab1 and Archipelago. BREAST CANCER RESEARCH AND TREATMENT. vol. 88, S180-S180.
Musat M, Vax VV, Borboli N et al.(2004). Cell cycle dysregulation in pituitary oncogenesis. FRONT HORM RES vol. 32, 34-62.
Vax V, Goncharov N, Kadashev B et al. (2004). Gonadotropinomas & non-functioning pituitary tumours in males. PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY. 413-419.
KORBONITS MJ, Grossman AB(2004). Non-growth hormone endocrine actions of ghrelin. Ghrelin and growth hormone secretagogues73-88.
Korbonits M, Morris DG, Nanzer A et al.(2004). Role of regulatory factors in pituitary tumour formation. Front Horm Res vol. 32, 63-95.
Morris DG, Kola B, Borboli N et al.(2003). Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. J Clin Endocrinol Metab vol. 88, (12) 6080-6087.
Kola B, Korbonits M, Diaz-Cano S et al.(2003). Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin Endocrinol (Oxf) vol. 59, (3) 328-338.
Vax VV, Gueorguiev M, Dedov II et al.(2003). The Krüppel-like transcription factor 6 gene in sporadic pituitary tumours. Endocr Relat Cancer vol. 10, (3) 397-402.
Vax VV, Bibi R, Diaz-Cano S et al.(2003). Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. J Endocrinol vol. 178, (2) 301-310.
Mozid AM, Tringali G, Forsling ML et al.(2003). Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm Metab Res vol. 35, (8) 455-459.
Orkin RD, New DI, Norman D et al.(2003). Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. J ENDOCRINOL INVEST vol. 26, (8) 743-747.
Svensson J, Monson JP, Vetter T et al.(2003). Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. CLIN ENDOCRINOL vol. 58, (5) 572-580.
KORBONITS MJ, Grossman AB, Kola B et al.(2003). Expression of the F-box protein Skp-2 in normal and tumorous pituitary. Pituitary vol. 5, 235-242.
KORBONITS MJ, Grossman AB, Bandeira F et al.(2003). Hyperprolactinaemia. Endocrinology and Diabetes105-116.
Pyle ME, Korbonits M, Gueorguiev M et al.(2003). Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol vol. 176, (1) 103-110.
Kaltsas GA, Kola B, Borboli N et al.(2002). Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol (Oxf) vol. 57, (4) 443-448.
Korbonits M, Gueorguiev M, O'Grady E et al.(2002). A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab vol. 87, (8) 4005-4008.
Gueorguiev M, Korbonits M, O'Grady E et al. (2002). Mutation in the ghrelin gene associated with increase in body weight and reduction of insulin secretion in tall, obese children. DIABETOLOGIA. vol. 45, A176-A176.
Korbonits M, Chahal HS, Kaltsas G et al.(2002). Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab vol. 87, (6) 2635-2643.
Gnanapavan S, Kola B, Bustin SA et al.(2002). The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J CLIN ENDOCR METAB vol. 87, (6) 2988-2991.
Newell-Price J, Morris DG, Drake WM et al.(2002). Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J CLIN ENDOCR METAB vol. 87, (4) 1640-1645.
Isidori AM, Kaltsas GA, Korbonits M et al.(2002). Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease. J Clin Endocrinol Metab vol. 87, (4) 1834-1840.
Musat M, Korbonits M, Pyle M et al.(2002). The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors. Pituitary vol. 5, (4) 235-242.
KORBONITS MJ(2002). Tumours and Humors. Central and Peripheral Mechanisms in Pituitary Disease vol. 87, 201-218.
Korbonits M, Bujalska I, Shimojo M et al.(2001). Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: Induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. J CLIN ENDOCR METAB vol. 86, (6) 2728-2733.
Korbonits M, Chitnis MM, Gueorguiev M et al.(2001). The release of leptin and its effect on hormone release from human pituitary adenomas. Clin Endocrinol (Oxf) vol. 54, (6) 781-789.
Kaltsas G, Korbonits M, Heintz E et al.(2001). Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J CLIN ENDOCR METAB vol. 86, (2) 895-902.
Korbonits M, Kojima M, Kangawa K et al.(2001). Presence of ghrelin in normal and adenomatous human pituitary. Endocrine vol. 14, (1) 101-104.
Korbonits M, Bustin SA, Kojima M et al.(2001). The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab vol. 86, (2) 881-887.
KORBONITS MJ, Grossman AB, Bonthron DT et al.(2001). Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest vol. 107, R31-R36.
KORBONITS MJ, Gueorguiev M, Goth MI(2001). Leptin and puberty - a review. Pituitary vol. 4, (1-2) 79-86.
Korbonits M, Chitnis MM, Gueorguiev M et al.(2001). Leptin in pituitary adenomas--a novel paracrine regulatory system. Pituitary vol. 4, (1-2) 49-55.
Kaltsas GA, Korbonits M, Isidori AM et al.(2000). How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?. Clin Endocrinol (Oxf) vol. 53, (4) 493-500.
Putignano P, Kaltsas GA, Korbonits M et al.(2000). Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment. J Clin Endocrinol Metab vol. 85, (9) 3309-3312.
Jordan S, Lidhar K, Korbonits M et al.(2000). Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol vol. 143, (1) R1-R6.
Skelly RH, Korbonits M, Grossman A et al.(2000). Expression of the pituitary transcription factor Ptx-1, but not that of the trans-activating factor prop-1, is reduced in human corticotroph adenomas and is associated with decreased alpha-subunit secretion. J Clin Endocrinol Metab vol. 85, (7) 2537-2542.
Korbonits M, Grossman AB(2000). Drug-induced hyperprolactinaemia. Prescribers' Journal vol. 40, (2) 157-164.
Lidhar K, Korbonits M, Jordan S et al.(1999). Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab vol. 84, (10) 3823-3830.
Korbonits M, Kaltsas G, Perry LA et al.(1999). Hexarelin as a test of pituitary reserve in patients with pituitary disease. Clin Endocrinol (Oxf) vol. 51, (3) 369-375.
Korbonits M, Little JA, Forsling ML et al.(1999). The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants. J Neuroendocrinol vol. 11, (7) 521-528.
Korbonits M, Kaltsas G, Perry LA et al.(1999). The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab vol. 84, (7) 2489-2495.
Satta MA, Korbonits M, Jacobs RA et al.(1999). Expression of menin gene mRNA in pituitary tumours. Eur J Endocrinol vol. 140, (4) 358-361.
Korbonits M, Ciccarelli E, Ghigo E et al. (1999). The growth hormone secretagogue receptor. Growth Horm IGF Res. vol. 9 Suppl A, 93-99.
Korbonits M(1998). Leptin and the thyroid--a puzzle with missing pieces. Clin Endocrinol (Oxf) vol. 49, (5) 569-572.
Korbonits M, Jacobs RA, Aylwin SJ et al.(1998). Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors. J Clin Endocrinol Metab vol. 83, (10) 3624-3630.
Trainer PJ, Woods RJ, Korbonits M et al.(1998). The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. J Clin Endocrinol Metab vol. 83, (5) 1611-1614.
Korbonits M, Trainer PJ, Little JA et al.(1997). Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity. Clin Endocrinol (Oxf) vol. 46, (6) 751-757.
Korbonits M, Trainer PJ, Nelson ML et al.(1996). Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Clin Endocrinol (Oxf) vol. 45, (6) 699-706.
Korbonits M, Grossman AB(1996). [Growth hormone-releasing peptides (GHRP) and their analogues]. Orv Hetil vol. 137, (45) 2503-2509.
Korbonits M, Trainer PJ, Fanciulli G et al.(1996). L-arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide. Eur J Endocrinol vol. 135, (5) 543-547.
Korbonits M, Little JA, Camacho-Hübner C et al.(1996). Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitro. Growth Regul vol. 6, (2) 110-120.
Korbonits M, Besser M(1996). Diagnosis of growth hormone deficiency in adults. Horm Res vol. 46, (4-5) 174-182.
Savage MO, Korbonits M, Grossman AB(1996). [Clinical value of neuropeptides GHRH and GHRP]. Arch Pediatr vol. 3 Suppl 1, 148s-150s.
Korbonits M, Trainer PJ, Besser GM(1995). The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clin Endocrinol (Oxf) vol. 43, (3) 365-371.
Korbonits M, Trainer PJ, Edwards R et al.(1995). Benzodiazepines attenuate the pituitary-adrenal responses to corticotrophin-releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome. Clin Endocrinol (Oxf) vol. 43, (1) 29-35.
Korbonits M, Grossman AB(1995). Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends in Endocrinology and Metabolism vol. 6, (2) 43-49.
Thomas JDJ, Dattani A, Zemrak F et al.(2016). Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance. Endocrine
Yelamanchi SD, Solanki HS, Radhakrishnan A et al.(2016). Signaling network map of the aryl hydrocarbon receptor. Journal of Cell Communication and Signaling
Return to top